ArticleInternational urology and nephrology2025
Comparison of urinary tract dilation and society for fetal urology classifications in predicting indication and success of pyeloplasty in ureteropelvic junction obstruction.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to compare the ability of the Urinary Tract Dilatation (UTD) and Society for Fetal Urology (SFU) classification systems to predict the need for treatment and the success of the applied treatment methods for ureteropelvic junction obstruction (UPJO) patients. PATIENTS AND
methodsThe study included 239 patients who underwent follow-up, J stent insertion, or pyeloplasty due to UPJO between 2012 and 2022, with complete long-term follow-up data. During the follow-up period, failure was defined as fractional function decrease, lack of diuretic response, t1/2 increase, persistent symptoms, or an increase in hydronephrosis degree. Treatment modality and success were compared between UTD and SFU subgroups.
resultsIn the study, a total of 239 patients were included, of whom 67 (28%) were female and 172 (72%) were male. The median age of the patients was 84 months (2-154.5 months), and the mean follow-up duration was 55 months (13-130 months). UPJO was observed in 99 (41.4%) patients in the right kidney and 140 (58.6%) patients in the left kidney. There were no statistically significant differences between the groups in terms of age, gender, side, and comorbidities (p = 0.165, p = 0.620, p = 0.441, and p = 0.768, respectively). We found a strong correlation between UTD and SFU classifications for patient treatment success, while a moderate correlation was observed for treatment failure (r = 0.816 and r = 0.575, respectively). Confirmed by both UTD and SFU classifications, conservative treatment was the appropriate choice for success in low-grade diseases, while pyeloplasty should be offered in high-grade diseases.
conclusionBoth UTD and SFU classification systems show similar ability to predict the success rates regarding treatment methods for UPJO with a higher degree of confidence.
Indexed as
Identifiers
40411626What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.